Why Mosar ?
The control and combat of AMRB is an urgent public health issue. Each year 5 million patients develop a nosocomial infections in healthcare settings in the EU and 50 000 patients die.
Among nosocomial infections, those caused by antimicrobial-resistant bacteria (AMRB) account for an increasing proportion worldwide and the situation is worsening. This situation is an extremely worrying since infections caused by AMRB are more severe and require longer and more complex treatments than those caused by susceptible bacteria.
Nosocomial infections are also significantly more difficult and expensive to diagnose and to treat, and are associated with adverse outcomes such as delayed appropriate therapy or even failure of therapy, prolonged length of hospital stay, and increased mortality.
Thus MOSAR aims to integrate and coordinate the activities of physicians and scientists from 16 institutions in 9 European Member or Associated countries in order to combat the antimicrobial resistance of bacteria responsible for major and emerging nosocomial infections in hospitals.
Short video presenting the MOSAR project and objectives
MOSAR major achievements to date
At the start of the third year, all hospitals had been recruited to participate to the trial, and thus during the third year of the MOSAR programme, our effort focused mainly on completing the clinical trials and initiating the characterization of bacterial isolates recovered. More detailed information, as well as MOSAR presentation poster, are available in the section "Our activities".
For more information on the MOSAR project, please download MOSAR Presentation Leaflet, available in the following languages:
To have access to the latest news published by MOSAR Consortium, please visit our
"General Information" section.
MOSAR is an Integrated Project supported for 5 years by the European Commission under the Life Science Health Priority of the Sixth Framework Program.